Cart
sales@molnova.com
KU-2285
CAS No. 121077-11-0
KU-2285( —— )
Catalog No. M34633 CAS No. 121077-11-0
KU-2285 shows anti-tumor, anti-metastatic and anti-colony forming effects on mouse melanoma B16.KU-2285 can be used to study pancreatic cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 686 | In Stock |
|
| 10MG | 938 | In Stock |
|
| 25MG | 1444 | In Stock |
|
| 50MG | 1841 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameKU-2285
-
NoteResearch use only, not for human use.
-
Brief DescriptionKU-2285 shows anti-tumor, anti-metastatic and anti-colony forming effects on mouse melanoma B16.KU-2285 can be used to study pancreatic cancer.
-
DescriptionKU-2285 shows anti-tumor, anti-metastatic and anti-colony forming effects on mouse melanoma B16.KU-2285 can be used to study pancreatic cancer.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number121077-11-0
-
Formula Weight264.19
-
Molecular FormulaC8H10F2N4O4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(C(F)(CN1C=CN=C1[N+]([O-])=O)F)NCCO
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
2-Carboxybenzaldehyd...
The major peak of 2-Carboxybenzaldehyde reductase activity in human liver co-purifies with hAFAR protein. Sulphydryl substances and some proteins play important roles in preserving the molecular and catalytic properties of 2-Carboxybenzaldehyde reductase.
-
NADPH tetrasodium sa...
NADPH tetrasodium salt is the reduced form of the electron acceptor nicotinamide adenine dinucleotide phosphate (NADP+) and acts as an electron donor in various biological reactions.
-
Sitostenone
Sitostenone has antioxidation activity. Stigmasta-4-en-3-one(Sitostenone) can be used for the treatment of androgen-dependent diseases, especially for the treatment of benign prostatic hyperplasia.
